One Plus One Equals Three For Calluna
Two early-stage companies have merged to form Calluna Therapeutics, which is targeting immunological diseases and hopes to get to proof of concept by mid-2026.
Two early-stage companies have merged to form Calluna Therapeutics, which is targeting immunological diseases and hopes to get to proof of concept by mid-2026.